Roche's Enspryng wins FDA Priority Review for thyroid eye disease

Roche has announced that the US Food and Drug Administration has accepted and granted Priority Review to a supplemental Biologics Licence Application (sBLA) for Enspryng (satralizumab) in thyroid eye disease (TED). The FDA is expected to issue a decision by 15 October 2026, a timeline that puts the drug on course to become the first subcutaneous, at-home treatment option for the condition if approved.

The filing is supported by results from the two identically designed Phase 3 SatraGO-1 and SatraGO-2 studies, which together enrolled 258 patients across 19 countries. Data were first presented publicly at the American Society of Ophthalmic Plastic and Reconstructive Surgery symposium in October 2025.

Trial data

In the pivotal proptosis endpoint at week 24, 53% of Enspryng-treated patients in SatraGO-2 achieved a reduction in eye protrusion of at least 2 mm versus 23% on placebo, a difference that met statistical significance. In SatraGO-1, the response rate was 49% against 31% for placebo; that numerical gap did not reach statistical significance, though Roche describes it as confirmatory evidence. Across both studies, between 78% and 90% of patients with active TED saw improvements in clinical activity score, and between 44% and 61% experienced relief from diplopia. No new safety signals were identified, and the profile was described as consistent with Enspryng's established record in neuromyelitis optica spectrum disorder (NMOSD), where the drug is already approved in approximately 90 countries.

Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the Priority Review acceptance was "an important step toward expanding treatment options for people living with thyroid eye disease," adding that the subcutaneous route of administration could combine clinical benefit with at-home convenience.

Market and competitive context

TED affects roughly 155 people per 100,000, most commonly in association with hyperthyroidism, and carries significant quality-of-life impact through proptosis, diplopia and potential sight loss. The current approved treatment landscape includes teprotumumab (Tepezza, Amgen/Horizon Therapeutics), an IGF-1R inhibitor administered intravenously in a clinic setting. A subcutaneous self-injection option would represent a meaningful shift in the care model, addressing a longstanding patient preference for convenience and reducing the burden on infusion services.

Satralizumab targets IL-6 receptor activity via a recycling antibody technology designed to sustain suppression of inflammatory pathways. Its mechanism is distinct from teprotumumab's IGF-1R blockade, offering physicians a potential alternative for patients who do not respond to or tolerate existing therapy. Roche is also pursuing Enspryng in autoimmune encephalitis and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where a positive Phase 3 readout was recently announced and regulatory submissions are planned. That breadth of neurological autoimmune indications could reinforce payer and prescriber familiarity with the molecule.

The October 2026 PDUFA date will be closely watched by the ophthalmology and neuroimmunology communities. Analysts will focus on whether the agency accepts the mixed statistical picture from SatraGO-1 alongside the positive SatraGO-2 result, and on the label language around administration setting if approval is granted.